Aspen Neuroscience (ASPE) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
26 Oct, 2026Company overview and business model
Clinical-stage regenerative medicine developer of autologous iPSC-derived therapies for CNS diseases; lead candidate sasineprocel is a single-dose cell replacement therapy for Parkinson’s disease (PD).
Sasineprocel uses patient-derived cells intended to replace lost dopamine neurons; the autologous approach is designed to avoid post-treatment immunosuppression and support durable neural integration.
The pipeline also includes gene-edited autologous microglia precursors for pediatric leukodystrophies; IND-enabling studies are expected to begin in H2 2027.
Strategy includes advancing sasineprocel to Phase 3, expanding into genetic PD, automating manufacturing for potential North American commercialization, and developing additional CNS programs.
Financial performance and metrics
Net loss was $62.1M in FY2025 versus $48.6M in FY2024; H1 2026 net loss was $36.5M versus $31.8M in H1 2025.
H1 2026 R&D expense was $28.5M versus $20.8M in H1 2025; G&A was $9.8M versus $10.1M.
Cash, cash equivalents and marketable securities were $72.4M at June 30, 2026; accumulated deficit was $264.9M, with substantial doubt about ability to continue as a going concern without financing.
Existing resources plus offering proceeds are projected to fund operations into H2 2028, but are not expected to complete the Phase 1/2a or Phase 3 trials; further capital will be needed.
Use of proceeds and capital allocation
Estimated net proceeds are $134.5M at the assumed $16.00 midpoint, or $155.4M if the underwriters exercise the option in full.
Planned allocation: $8.0M to the Phase 1/2a ASPIRO trial; $110.0M to initiate and fund Phase 3 in sporadic and genetic PD; $4.0M to microglia development and IND-enabling studies; remainder for working capital and general purposes.
Potential additional uses include licensing, acquiring or investing in complementary businesses, technologies, products or assets; no current commitments are described.
